Huren Sivaraj
@HSivarajMD
Followers
72
Following
62
Media
2
Statuses
204
Oncologist. CEO and Co-founder of Oncoshot Cancer Collaborative Platform
Joined November 2011
Can’t wait to watch @ZakirHtabla and other maestros at @esplanade_sg tmrw. My 4 year old, whose morning routine involves drinking milk while watching the YouTube recording of zh and @Rakeshflute in Poland is upset that he can’t come. Appeasing him now with a few repeats!
0
0
0
A webinar on “Managing with cancer during COVID-19” with SG Medical experts organised by the Singapore Society of Oncology. An effort by the SG medical community to support patients and caregivers!.#sgunited #covid19 #cancer @oncoshot @leehsienloong @GANKIMYONG.
Webinar MANAGING WITH CANCER DURING COVID-19 s
0
0
0
RT @oncoshot: Oncoshot has tools to help patients and Oncologists find suitable clinical trials in REALTIME. Help us understand you better….
0
5
0
RT @pashtoonkasi: #CRCSM Just looking back at the developments this year for colorectal cancer: From treating with doublet or triplet chemo….
0
4
0
RT @ClinTrials365: Who benefits from introducing digital health in clinical trials? #mhealth #IoT #BigData #patient….
0
5
0
RT @ivybelkins: Testing for mutations upon #lungcancer diagnosis is so important!!! More evidence for starting with TKI treatment for EGFR….
0
7
0
RT @RielyMD: Important to highlight PD-l1 negative patients didn’t appear to benefit (PFS or OS). We should look at biomarker data to help….
0
17
0
RT @LungConsultant: NELSON trial results of CT screening for lung cancer still sinking in. After years of waiting, the implementation of….
0
36
0
RT @DRBLUNGS: NELSON results should now be enough to convince everyone that there is no justification for delays in implementing LDCT scree….
0
31
0
RT @TommyJohn00: Liu: IMPower133. Another game changing abstract. Curves separate at 6 months. OS HR 0.7, 2 month OS benefit. No diff in OR….
0
7
0
RT @marinagarassino: Unbelievable that #EMA did non give the #durvalumab label in #PDL1 negative and Unknown for a post hoc non pre planned….
0
9
0
RT @dplanchard: MET as a new target ?capmatinib+gefitinib in EGFRmut pts with MET-dysregulated NSCLC (phase Ib/II study). JCO editorial . ….
ascopubs.org
0
12
0
RT @DanChenMDPhD: @Tony_Calles @IASLC The immunosuppressive mechanisms present in Small Cell Lung Cancer will shape up to be some of the mo….
0
6
0
RT @swami2005: India's first lady Cardiologist, Dr. Padmawati Sivaramakrishna Iyer turned 101yrs on 20th June 2018. She is director of th….
0
3K
0
RT @CurrentOncology: Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell #….
0
1
0
RT @LLandLeukaemia: YES YES YES! HE DID IT! The Big Moment. Hugo’s last dose of chemo. The End of Treatment. ❤️🎗#TeamHugo #HeKickedCancersB….
0
85
0